Alon Witztum

Alon Witztum

Auto-generated profile, based on publicly available information

Alon Witztum

Department of Radiation Oncology, University of California San Francisco , San Francisco, CA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2026 in Neuro-Oncology
Verified
Journal Article
Closed access
BBBrooke C Braman
Brooke C Braman
MCMartha A Cady
Martha A Cady
AMAllison A Merz-Herrala
Allison A Merz-Herrala
AWAlon Witztum
Alon Witztum
ZAZora Arum
Zora Arum
DRDavid R Raleigh
David R Raleigh
Meningiomas are among the few intracranial tumors that are more common in females than males. The majority of meningiomas express progesterone receptor (PR), and differences in exposure to progestogens are thought to contribute to sex-based disparity in meningioma. Previous epidemiological and clinical data have demonstrated that multiple progestins, such as cyproterone acetate (CPA), are linked to meningioma. More recently, international epidemiological studies have found a significantly increased risk of meningioma with depot medroxyprogesterone acetate (DMPA), a widely used injectable contraceptive sold under the trade name Depo-Provera. Although the absolute risk of meningioma remains small, exposure to DMPA increases the risk of meningioma by 1.5- to 5.5-fold. DMPA-associated meningiomas are clinically significant, as the risk of craniotomy for tumor resection, not just the risk of tumor diagnosis, is elevated after DMPA exposure. These data suggest that DMPA should be avoided in individuals with a history of meningioma when alternatives are available. The risk of meningioma should be discussed with patients during DMPA counseling, and the utility of screening patients with prolonged DMPA exposure for meningiomas should be investigated. Further work is needed to elucidate the mechanisms of PR signaling in meningioma and to understand the complex interplay of tumor genomics, hormone exposure and signaling, and social and structural drivers of health that may contribute to disparities in meningioma.

26 May 2026 in Neuro-Oncology Practice
Verified
Journal Article
Open access
ZAZora Arum
Zora Arum
RMRamin A Morshed
Ramin A Morshed
BBBrooke C Braman
Brooke C Braman
KMKanish Mirchia
Kanish Mirchia
JVJavier E Villanueva-Meyer
Javier E Villanueva-Meyer
DRDavid R Raleigh
David R Raleigh
Background: Standard treatments for meningioma include surgery and radiotherapy, but the timing and technical details of these treatments are debated, particularly as advances in meningioma biology expand options for treatment. Patients with meningioma may experience adverse quality-of-life and neurocognitive sequelae following diagnosis and treatment, and survivorship resources for these patients are limited. Methods: We initiated a Multidisciplinary Meningioma Program (MMP) to advance the care of patients at our institution in September 2024. The MMP consists of synergistic clinical, scientific, and survivorship resources, including a weekly tumor board and multidisciplinary clinic, clinical trials and prospective registries for translational research, a meningioma-specific support group, and basic and translational research. In this article, we describe the implementation and initial patient-facing aspects of the MMP. Results: In the first 15 months of the MMP, 602 cases were discussed at the MMP tumor board, and 142 patients were seen in consultation in the MMP multidisciplinary clinic. Twelve percent of patients discussed in the MMP tumor board were offered clinical trial enrollment, and 84% were offered prospective registry enrollment. Participants in the MMP support group cited informational and emotional benefits. Following implementation of the MMP, the clinical volume of consultations for meningioma increased by 87.0%-533.3%, and the volume of treatments increased by 42.1%-115.2% across clinical departments. Conclusions: Through creation of a multidisciplinary program for meningioma treatment, research, and support services, we enabled consensus clinical recommendations, streamlined enrollment on clinical trials and prospective registries, improved access to support services, and increased patient volume.

13 November 2024 in Practical Radiation Oncology
Verified
Journal Article
Closed access
AWAlon Witztum
Alon Witztum
YJYounes Jourani
Younes Jourani
EHEmily Y. Hirata
Emily Y. Hirata
TMTodd McNutt
Todd McNutt
TTTony Tadic
Tony Tadic
CMCharles S. Mayo
Charles S. Mayo